Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound…
An institutional-grade, numbers-driven thesis on IXHL — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Incannex Healthcare Limited (IXHL) 55/100 with a 12-month base-case forecast of $1.99 — -49.9% versus the current price of $3.97. Incannex Healthcare Limited trades at $3.97 in the Healthcare sector, with a market capitalisation of $47.5M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for IXHL is $1.99, implying -49.9% versus the current price. The model's 12-month scenario range runs from $0.52 (bear) to $4.02 (bull), with a base case of $1.99.
On the fundamentals, Incannex Healthcare Limited shows a P/E of -1.8, trailing revenue of $86000, revenue growth of +616.7% YoY. This page also tracks IXHL's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
IXHL currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. Our 12-month price target of $1.99 implies -49.9% from $3.97. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for IXHL is $1.99, about -49.9% versus the latest price of $3.97.
TradersQuant's 12-month model forecast for IXHL is a base case of $1.99, ranging from $0.52 (bear) to $4.02 (bull), an expected return of -50.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for IXHL over the next 12 months is $1.99 in the base case (bear $0.52, bull $4.02), versus today's price of $3.97. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for IXHL — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates IXHL's fair value at $5.06, implying +27.4% of expected upside versus the current price.
Incannex Healthcare Limited does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
